||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Evgen Pharma Share Discussion Threads
Showing 2176 to 2200 of 2200 messages
|I don't really understand why the share price continues to move downwards when there is the possibility of some positive news flow later this year.
Perhaps there's en expectation of a placing in the near future?|
pumped and dumped
|Wow more good news evg|
|A takeover is another possibility. And they are usually good things ( Unless you're a Poundland shareholder: (|
|TimboFair enuf but this means that further positive results will propel the shares to a new levelAgreed 100p|
Whilst the granting of orphan status is welcome, it was widely anticipated and it was not difficult to work out that Evgen were likely to be granted orphan status due to the rarity of the condition and the current absence of an effective treatment.
Having said that, if the SAH Phase II study meets its primary end point (results due early 2018), we will undoubtedly see £1 per share at some point in the future.|
|Surprised these aren't back at float price after ydays great newsBroken the USA marketUpside to 100p|
|This is groundbreaking Shares floated at 37pShould get to 37p tomorrow Northland had 79p tgtNow what?100p??!!|
|going well, super news, glad I added at start of August to average down, now looking a very profitable investment, but not for taking profit as I do believe in this for long term and hopes of doubling ay least.|
|Ive had this share for best part of a year - best news yet|
|Game changer Amazing news|
|yep see that got in when VOX Markets sent me a text 2 mins after the RNS dropped|
|Evgen Pharma PLC on Wednesday said its drug for the treatment of subarachnoid haemorrhage has been granted orphan drug designation by the US Food & Drug Administration.
Subarachnoid haemorrhage is a rare form of stroke in which blood from a ruptured aneurysm enters the protective space around the brain.
The SFX-01 drug, a synthetic and stabilised version of sulforaphane, is currently in a Phase II trial in the UK.
This designation in the US gives its drug the potential for US market exclusivity for seven years from the date of marketing approval, the company said.
The orphan drug designation programme provides orphan status to drugs and biologics for rare diseases or disorders affecting fewer than 200,000 people in the US.
SFX-01 specifically targets the Nrf-2 pathway, which reduces the oxidative stress and toxicity caused by free haemoglobin from the haemorrhage.
"The receipt of orphan drug designation in subarachnoid haemorrhage is highly significant for Evgen Pharma and for our clinical programme in subarachnoid haemorrhage, a devastating condition with high unmet clinical need," said Chief Executive Stephen Franklin.
"Evgen's SFX-01, has the potential to represent the first step-change improvement in the treatment of subarachnoid haemorrhage in more than 20 years in that it targets the principal drivers of the delayed vasospasm. Recruitment in our Phase II study of SFX-01 in subarachnoid haemorrhage remains on track and we look forward to the results of the study in due course," Franklin said.
Shares in Evgen were up 25% at 32.00 pence on Wednesday afternoon.|
|very nice too gla|
|Orphan status from FDA in US for SAH is great news!!|
|This is great newsNo reason why this should be trading at a discount to placing price of 37p|
|All looking ...sp creeping up!|
|Looks like it bottomed out and on the way up, I did like the video presentation, seems to have some substance and potential, I am looking at losses here at this time but added a few to average done. I think this is a long term investment and have high hopes.|
|lifting off try buying|
|EVGEN PHARMA (EVG) 5 STAR TOP PICK
EVGEN PHARMA BUY
Growth Company Investor 28 JULY 2016
Evgen Pharma (AIM: EVG)
|EVGEN PHARMA BUY
|EVGEN PHARMA (EVG) 5 STAR TOP PICK
|Evgen Pharma (LON:EVG) ready to prove broccoli drug’s worth
26th July 2016
Can a humble molecule with a heritage in broccoli really cure any number of ailments? That’s the premise behind Evgen Pharma (LON:EVG) and chief executive Stephen Franklin says that after ...|
|These are looking perky again this morning
It's worth having a look at the AIM admission document which gives a few clues to who might want to get out at what price.
The IPO price was 37p/share. On admission (October 2015) there were a lot of CLNs converted at half the IPO price (i.e. 18.5p) and 80% of the IPO price (29.6p)|
|Evgen Pharma (EVG)
25th July 2016
The cash ensures Evgen, led by Dr Stephen Franklin, has the financial wherewithal to complete two Phase II trials. Patients in the first group, suffering SAH, are already being dosed. ..|